

## EMOSIS is re-certified ISO 9001:2015 and ISO 13485:2016

The company confirms the sustainability of its commitment towards highest quality standards

Strasbourg, May 16<sup>th</sup> 2019

Emosis, a medical device company specializing in cell-based hemostasis diagnostics, is glad to announce that the company has recently been re-certified for ISO 9001:2015 and ISO 13485:2016 certificates.

The re-certification for both standards imply that the quality procedures set up by Emosis are sustainable and compliant with the quality standards demanded by the ISO – International Organization for Standardization - regarding the design, manufacturing and sale of In Vitro diagnostics tests.

Emosis is moving forward, and aims to move towards sustainability in excellence and in compliance with highest quality standards.

This allows Emosis to reassure its partners and clients about its commitment, in true transparency.

ISO 9001:2015 is the most updated standard of its kind and it focuses on quality management systems and performance. Its requirements lead companies to develop a management system that aligns quality with their wider business strategy.

As for ISO 13485:2016, it specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and IVD that consistently meet customer and applicable regulatory requirements.

Obtaining these certifications was

a challenge, and gaining a re-certification is another milestone in the story of Emosis' developments.

Dr. Frederic Allemand, CEO of Emosis, declared: "These re-certifications are definitely a step we are proud of, as they reflect our commitment and the excellence pathway we have engraved since Emosis' start. More than ever, we are focusing our efforts towards highest standards of process quality, to provide the medical world with paradigm-shifting solutions in IVD for Hemostasis".

### ABOUT EMOSIS

*Emosis is an innovative medical device company specializing in cytomolecular diagnostics of hemostasis and thrombosis disorders. The company is dedicated to the clinically-centered development, marketing and commercialization of first-in-class, on-demand and user-friendly assays, Emo-tests, to be routinely performed on the rapidly growing new generation of low cost and operator friendly flow cytometers. Emo-tests aim to inform physician medical decision with respect to bleeding or clotting events (or risk of) in a broad range of clinical settings, encompassing cardiovascular and neurovascular diseases, cancer, pregnancy, and pharmacological and non-pharmacological therapy management.*

